Author: Chang Chen; Jianying Huang; Zhenshun Cheng; Jianyuan Wu; Song Chen; Yongxi Zhang; Bo Chen; Mengxin Lu; Yongwen Luo; Jingyi Zhang; Ping Yin; Xinghuan Wang
Title: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial Document date: 2020_3_20
ID: 14he8n3u_41
Snippet: Additionally, because of the complexity of the disease, progression from moderate to severe/critical is possible. Terminating trial treatment to such patients from the study was considered unacceptable. Post-hoc analysis showed that both treatment and clinical classification contributed significantly to the primary outcome of clinical recovery rate at Day 7. Difference of the frequency of severe/critical patients between groups reached a marginal.....
Document: Additionally, because of the complexity of the disease, progression from moderate to severe/critical is possible. Terminating trial treatment to such patients from the study was considered unacceptable. Post-hoc analysis showed that both treatment and clinical classification contributed significantly to the primary outcome of clinical recovery rate at Day 7. Difference of the frequency of severe/critical patients between groups reached a marginal significance, which made an important impact on the trial outcome.
Search related documents:
Co phrase search for related documents- clinical recovery rate and primary outcome: 1, 2, 3, 4, 5, 6, 7, 8
- clinical recovery rate and recovery rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical recovery rate and study patient: 1
- clinical recovery rate primary outcome and moderate progression: 1
- clinical recovery rate primary outcome and primary outcome: 1, 2, 3, 4, 5
- clinical recovery rate primary outcome and recovery rate: 1, 2, 3, 4, 5
- clinical treatment and disease complexity: 1
- clinical treatment and group severe critical patient: 1
- clinical treatment and important impact: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- clinical treatment and moderate progression: 1, 2, 3
- clinical treatment and post hoc analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- clinical treatment and primary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical treatment and recovery rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical treatment and severe critical patient: 1
- clinical treatment and significantly contribute: 1, 2, 3, 4, 5
- clinical treatment and study patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical treatment and trial outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- disease complexity and study patient: 1, 2, 3
- group severe critical patient and severe critical patient: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date